6ACTIVITIES
1ORGS REPRESENTED
14BILLS
Organizations represented
1Orgs whose LD-2 filings list Justin as an active lobbyist, sorted by activity volume.
Bills they file on
14Topics in Filings
173Policy topics Justin files on across all their LD-2 activities.
FY 2025 Appropriations×20
FY 2026 Appropriations×13
Bio COMPETES×11
House GOP RFI on Supply Chain×8
Interagency Patent Coordination and Improvement Act×7
Show all 173 topics (+168 more) ▾
Prescription Pricing for the People Act×6
Preserve Access to Affordable Generics and Biosimilars Act×5
Stop STALLING Act×5
National Coverage Determination×5
BIOSECURE Act×4
Restrictions on Intellectual Property Rights×4
ORPHAN Cures Act×4
Pharmacy Benefit Manager Transparency Act×4
CMMI Authority×4
TRIPS Waiver×3
Development and Procurement Issues×3
Risky Research Review Act×3
Tropical Disease Priority Review Voucher×3
Development and Procurement×3
Funding for Strategic National Stockpile×3
FY 2026 Appropriations Funding for Antimicrobial Resistance×3
Monoclonal Antibody Coverage and Utilization×3
Prohibiting Adversarial Patents Act×2
Protecting Americans Data from Foreign Adversaries Act×2
Patent Eligibility Restoration Act×2
WHO Pandemic Preparedness Accord World Intellectual Property Office×2
Treaty on Intellectual Property×2
Genetic Resources, and Associated Traditional Knowledge World Trade Organization×2
340B Drug Discount Program×2
Executive Order on Access to Affordable Life-Saving Medications×2
Accelerated Approval Artificial Intelligence×2
Biosecurity Infrastructure for Operational×2
Biosimilar Copay×2
Interchangeability and Pharmacy Substitution×2
MINI Act×2
Climate Change×2
House GOP RFI on Data Privacy×2
Decentralized Clinical Trials×2
Promising Pathway Act×2
COVID-19 Lessons Learned×2
FDA Hiring Flexibility Drug Importation Drug Manufacturing×2
Quality & Distribution×2
Advanced Manufacturing×2
Drug Shortages×2
Safe, and Secure American Bioeconomy×2
Supply Chain Integrity and Traceability×2
Patent Thickets×2
Maintaining Investments and New Innovation×2
COVID-19 Pricing Related Provisions×2
Patient Cost-Sharing and Implementation×2
Strengthening Innovation in Medicare and Medicaid Act×2
MCM PRV×2
Advanced Research Projects Agency for Health×2
Alternative Payment Arrangements for Gene Therapies×2
Average Manufacturer Price Calculations×2
Coverage of Accelerated Approval Products×2
Drug Benefit Design×2
Encouraging Innovation Benefit Design to Lower Costs for Seniors Act×2
Pricing and Rebates×2
Value-Based Purchasing×2
National Defense Authorization Act×2
SUPPORT Act×2
Non-Opioid Analgesics×2
Coverage and Reimbursement Orphan Drug Issues×2
Give Kids a Chance Act×2
Pediatric Priority Review Voucher Program×2
R&D Funding for Medical Countermeasures×2
WHO Pandemic Preparedness Accord×2
HELP Copays Act×2
Administration Rebate Rule×2
Medicare Part B Physician-Administered Products×2
Patient Cost-Sharing and Smoothing×2
Protected Classes×2
Support of Patient Premiums and Cost-Sharing Obligations×2
Value-based Contracting and Communications Vaccines and Infectious Diseases×2
Adult Immunization×2
Countermeasures Injury Compensation Program×2
Maternal Immunization×2
MCM Manufacturing & Capacity×2
MCM PRV Reauthorization×2
Vaccine Injury Compensation Program×2
Vaccine Safety and Quality×2
Vaccine Safety net and Vaccine Infrastructure×2
Value of Vaccines and Vaccine Confidence×2
VICP Loopholes×2
Biodefense Research×2
Gene Editing×2
MCM PRV Program×2
HHS Reorganization×2
Pioneering Antimicrobial Subscriptions to End Upsurging Resistance×2
Funding for Biodefense/Biomedical/Emergency Preparedness Research×2
Pharmacy Benefit Managers Artificial Intelligence×1
Patentability of AI-Aided inventions Bayh-Dole Act/Tech Transfer×1
Invent Here×1
Make Here Act×1
Bayh-Dole Act×1
March-In Rights×1
Reasonable Pricing Clause Compulsory Licensing Data Privacy Issues×1
American Privacy Rights Act×1
Inventor Diversity for Economic Advancement×1
Drug Patenting×1
Affordable Prescriptions for Patients Act×1
Medication Affordability and Patient Integrity Act×1
Bill to address patent thickets×1
Title 35 to Address Infringements of Patents Claiming Biological Products×1
Protecting Consumer Access to Generic Drugs Act×1
FTC Orange Book Delisting Initiative×1
Orange Book Listing×1
PTO Proposed Rules on Terminal Disclaimer Practice×1
China Patent Reform×1
Patent Litigation Reform×1
USPTO Request for Comments: Experimental Use Defense 89 Fed×1
Reg 53963 Patenting of Biological Inventions×1
Section 101 Modernization×1
RESTORE Patent Rights Act×1
World Health Organization×1
Program & Oversight×1
American Pandemic Preparedness Plan×1
MCM PRV Program Reauthorization×1
NDAA×1
Reasonable Pricing Clauses in BARDA Contracts×1
CICP×1
White House National Biodefense Strategy×1
WHO Pandemic Preparedness Accord Biosimilars×1
Reimbursement Cell & Gene Therapy×1
FY 2026 Appropriations Data Privacy×1
Diversity & Inclusion×1
Clinical Trial Diversity Drug Evaluation and Review×1
Compounded Medicines×1
PBM Reform×1
VICP×1
CICP Funding for FDA×1
User Fees Funding for Health Resources and Services Administration×1
Funding for Womens Health Research International Reference Pricing Medicaid×1
Medicaid Drug Rebate Program Rule×1
Orphan Drug Tax Credit Pandemic Preparedness×1
Drug Supply Chain Management×1
Supply Chain Issues×1
Temporarily Refundable R&D Credit×1
Medical Countermeasures PRV Reauthorization×1
Lower Costs×1
More Cures Act×1
Vaccine and Antimicrobial Resistance Product Development and Incentives×1
State Strategic Stockpile Act×1
Executive Order on Achieving Efficiency Through State and Local Preparedness×1
Womens Health Research Pandemic Preparedness×1
340B Accountability Act×1
Program Implementation & Oversight×1
BSUFA Negotiations×1
General Cell & Gene Therapy×1
FY 2026 Appropriations Clinical Trial Data in China Data Privacy×1
General Diversity & Inclusion×1
Clinical Trial Diversity×1
General Drug Evaluation and Review×1
Compounded Medicines Drug Patenting×1
FY2025 Appropriations×1
PBN Reform×1
International Reference Pricing Foreign Drug Data Protection Laws×1
Regulatory Harmonization Funding for Antimicrobial Resistance×1
FY 2026 Appropriations International Reference Pricing Issues×1
Medicaid Drug Rebate Program×1
Innovation and Pediatric Drugs Act×1
Orphan Drug Tax Credit×1
CFIUS and Foreign Investment Drug Importation Drug Pricing×1
China Biotechnology Regulations×1
EU Ag-Biotech Policies×1
International Consistency of Regulation for Gene Edited Products×1
Korea Biotechnology Regulations×1
B5 Coalition on Supply Chain Resiliency×1
Medical Supply Chain Resiliency Act×1
Synthetic Biotech Pharmaceutical and Ag Biotech Tariffs US-China Trade Agreement×1
Ag-Biotech Provisions×1
IP Provisions World Health Organization×1
Pulled from the org’s own LD-2 disclosures. See the source filings ↓
Issue mix
LDA general-issue codes weighted by activity count.
Copyright/Patent/Trademark1
Health Issues1
Homeland Security1
Medical/Disease Research/Clinical Labs1
Medicare/Medicaid1
Trade (domestic/foreign)1